These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20388458)

  • 1. [Freezing of gait unresponsive to dopaminergic stimulation in patients with severe Parkinsonism].
    Vaamonde Gamo J; Cabello JP; Gallardo Alcañiz MJ; Flores Barragan JM; Carrasco García de León S; Ibañez Alonso RE
    Neurologia; 2010; 25(1):27-31. PubMed ID: 20388458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Schelosky L; Tison F; Rascol O
    JAMA Neurol; 2014 Jul; 71(7):884-90. PubMed ID: 24839938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Supra-on state freezing of gait: two case reports].
    Gallardo-Alcaniz MJ; Cabello-De la Rosa JP; Bravo-Gomez JJ; Diaz-Gomez S; Vaamonde-Gamo J
    Rev Neurol; 2016 Apr; 62(8):357-60. PubMed ID: 27064915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
    Kolls BJ; Stacy M
    Clin Neuropharmacol; 2006; 29(5):292-301. PubMed ID: 16960475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    Limousin P; Krack P; Pollak P; Benazzouz A; Ardouin C; Hoffmann D; Benabid AL
    N Engl J Med; 1998 Oct; 339(16):1105-11. PubMed ID: 9770557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
    Devos D; Bordet R; Defebvre L
    Rev Neurol (Paris); 2010 Feb; 166(2):168-77. PubMed ID: 19811797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.